痴呆症中血脑屏障的破坏:纳米解决方案作为新的治疗选择
Ceinwyn G Cooper1, Konstantinos N Kafetzis1, Adjanie Patabendige1,2
1Department of Biology, Edge Hill University, Ormskirk, UK.
The European journal of neuroscience
|December 28, 2023
概括
超过98%的中枢神经系统 (CNS) 药物由于血脑屏障 (BBB) 而失败. 这篇评论探讨了纳米粒子药物输送系统,以改善神经系统疾病 (如痴呆症) 的治疗方法.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 生物技术是生物技术.
背景情况:
- 中枢神经系统 (CNS) 药物开发面临着超过98%的失败率,主要是由于血脑屏障 (BBB) 限制了药物的透性.
- 神经系统疾病是导致死亡的首要原因,患病率不断增加,突显出迫切需要有效的中枢神经系统治疗.
- 在健康和疾病状态下了解BBB的结构,功能和传输机制对于治疗进步至关重要.
研究的目的:
- 审查BBB的结构和运输机制.
- 评估基于纳米粒子的药物输送系统,用于中枢神经系统疾病.
- 专注于这些系统在治疗痴呆症方面的潜力.
主要方法:
- 关于BBB运输系统的文献综述.
- 在中枢神经系统研究中对纳米粒子药物载体应用的分析.
- 评估现有关于神经疾病药物输送的研究.
主要成果:
- BBB对中枢神经系统的药物输送构成了重大障碍.
- 纳米粒子载体在准BBB运输系统方面表现有前途.
- 通过纳米颗粒的向输送可以提高痴呆症的治疗疗效.
结论:
- 开发有效的基于纳米粒子的药物递送系统对于推进中枢神经系统疾病治疗至关重要.
- 对BBB传输和纳米粒子载体的进一步研究可能会导致对痴呆症和其他神经疾病的新疗法.
- 提高BBB的透性是提高中枢神经系统候选药物的成功率的关键.
更多相关视频
09:10Author Spotlight: Advancing the Use of Tissue Chip Technology for Studying Human Tissues
Published on: January 12, 2024
2.9K
06:29Real-Time Intravital Multiphoton Microscopy to Visualize Focused Ultrasound and Microbubble Treatments to Increase Blood-Brain Barrier Permeability
Published on: February 5, 2022
4.4K
相关概念视频
The Blood-brain Barrier
47.4K
Overview
47.4K
Alzheimer's Disease: Treatment
195
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
195
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
127
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
127
